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Abstract
Background: Atherosclerosis is the main cause of mortality and morbidity in end stage renal
diseases (ESRD), especially in hemodialysis (HD) patients. In addition the classic risk factors for
atherosclerosis, non classical risk factors, such as high lipid peroxidation and low antioxidants, also,
are culprit in the pathogenesis.
Method:  We tested lipid peroxidation and total antioxidant levels in forty five stable
hyperlipidemic HD males (age range 40–60 years) before, after 45 and 90 days of prescription of
20 mg/day Lovastatin for three months. Malondialdehyde (MDA), as prototype of lipid
peroxidation, and total antioxidants (TA) were measured by flourimetric and spectrophotometric
assays, respectively.
Results: Serum triglyceride (Tg) (213.7 ± 112.4 mg/dl vs. 153.4 ± 54.8 mg/dl p = 0.003), serum
cholesterol (C) (185.8 ± 48.3 mg/dl vs. 149.3 ± 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl ± 48.9
vs. 84.8 ± 43.7 mg/d, p = 0.001), VLDL-C (40.7 ± 18.9 mg/dl vs. 30.7 ± 10.9 mg/dl, p = 0.025), MDA
(13.1 ± 3.5 nmol/ml vs. 1.27 ± 1 nmol/ml, p = 0.00), TA (0.98 ± 0.17 mmol/l vs. 1.28 ± 0.27 mmol/
l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 ± 7.7 mg/dl, p = 0.007) significantly were changed
by 3 months of Lovastatin therapy. These changes for HDL, VLDL and Tg after the 3 months were
more obvious than 45 days of Lovastatin therapy.
Conclusion: In HD patients serum lipids and their oxidations are increased. Both of them,
quantitatively and qualitatively, are improved by using of Lovastatin. The later would be due to
enhance of TA activity.
Introduction
End stage renal diseases (ESRD), despite of the different
etiologies, show a common hyperatherogenic state [1].
This may be due to existence of classic and nonclassic risk
factors. Hypertension, hyperlipidemia, diabetes mellitus
and cardiovascular hypertrophy as the first group, and
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hyperhemocycteinemia, increased Lpa, inflammation,
hyperfibrinogenemia and oxidative stresses, as the later,
are usually seen in ESRD. Higher levels of triglyceride (Tg)
and cholesterol (C) are observed in 33%–70% and 20%,
respectively [2]. Higher melvalonate level (due to its
retention in ESRD) [3], lower serum albumin concentra-
tion [4], lower lipoprotein lipase enzyme [5] and lower
Lecithin cholesterol acetyl transferase (LCAT) enzyme [6]
are responsible for dyslipidemia. Although hyperlipi-
demia due to the above causes is a main factor for athero-
sclerosis in ESRD, lipid peroxidation has an important
role, also [7]. Malondialdehyde (MDA), a prototype of
lipid peroxidation metabolite, is accumulated in ESRD.
Higher concentration of MDA may be due to defective
antioxidant defense in ESRD [8]. Statins by their inhibi-
tory actions on HMG-CoA enzyme and decrement of liver
Apo-B100 synthesis, and also by lowering of LDL suscep-
tibility to oxidation, are well known drugs for treatment of
hyperlipidemia of ESRD [9]. But their effect on total anti-
oxidant (TA) and their relationship with MDA need more
studies in HD patients.
Subjects and methods
In this study we selected 45 male HD patients. All of them
were dialyzing 3 times per week by cuprophane mem-
brane and acetate solution for 4 hours at each session.
Drug schedules did not change during the study. They had
negative history of hypolipidemic drug consumption at
least during the two months prior the study. The age range
was between 40 to 60 years. General conditions were sta-
ble in all of them, i.e. no active infection, no myocardial
infarction and no malnutrition were present. Lipopro-
teins, MDA and total antioxidant capacity were measured
by enzymatic, flourimetric and spectrophotometric
assays, respectively, at the time of zero, 1.5 and 3 months
after using of 20 mg/day of Lovastatin. Results of the
above data were analyzed by SPSS 10.05. ANOVA and
paired t test were used to comparison of parametric varia-
bles after Lovastatin therapy. Pearson's coefficient relation
and linear regression analysis were used for any possible
correlations between the variables. P < 0.05 was consid-
ered significant.
Results
At the beginning of the study the mean levels of total C,
Tg, LDL-C, VLDL-C, HDL-C, were 185.8 ± 48.3 mg/dl,
213.7 ± 112.4 mg/dl, 120.1 ± 48.9 mg/dl, 40.7 ± 18.9 mg/
dl and 24.9 ± 11.1 mg/dl, respectively. MDA level and TA
activity were 13.1 ± 3.5 nmol/ml and 0.98 ± 0.17 mmol/
l, respectively (Table 1). 45 days after treatment by Lovas-
tatin significant decrease in levels of total C (150.9 ± 32
mg/dl, p = 0.002), LDL-C (83.9 ± 38.3, p = 0.001), VLDL-
C (36.6 ± 15.6 mg/dl, p = 0.001) and MDA (3.68 ± 2.6
mg/dl, p = 0.000) were observed. But serum levels of Tg
(183.3 ± 78.1 mg/dl, p = 0.064) and HDL-C (29 ± 12.2
mg/dl, p = 0.17) did not change significantly. It was also
a significant increase in TA level after this period of Lovas-
tatin therapy (1.16 ± 0.29 mmol/l, p = 0.022) (fig. 1).
After 3 months of Lovastatin therapy the hypolipidemic
effect on total C, LDL-C, VLDL-C was maintained, even
more than before. In addition serum levels of HDL-C
increased (31.4 ± 7.7 mg/dl, p = 0.007) and Tg decreased
(153.4 ± 54.8 mg/dl, p = 0.003), significantly. At that time
more obvious decrease in serum MDA (1.27 ± 1 nmol/ml,
p = 0.00) and increase in TA activity (1.28 ± 0.27 mmol/l,
p = 0.001) was observed, also (fig. 2). Although it was not
a significant at the base It was an inverse linear correla-
tions between TA activity and serum level of MDA during
Lovastatin therapy, especially at the 90th day of Lovastatin
administration (r = -0.7, p < 0.05), Although, such a sig-
nificant correlation was not present at the pretreatment
period.
Discussion
In this study we showed that hyperlipidemia, especially
hypertryglyceridemia, is common in HD patients. In other
studies its prevalence has been reported up to 70% in
ESRD [2]. Despite of hyperlipidemia quantitatively, as a
main factor of atherosclerosis, changes of lipid qualities,
also, are among the important risk factors [10]. The later
is not improved after beginning of dialysis, even it may
becomes more severe [11].
Reactive oxygen species (ROS), contributory to mitochon-
drial electron transport and superoxide formation, affect
lipids and eventually leads to lipid peroxidation in HD
Table 1: Serum lipoproteins, MDA and total antioxidants before and after beginning of Lovastatin at the end of 1.5 and 3 months.
markers time Cholesterol
(mg/dl)
LDL-C (mg/dl) VLDL-C (mg/dl) HDL-C (mg/dl) TG (mg/dl) MDA (nmol/ml) Total Antioxidant
(mmol/ml)
Pre Lovastatin 185.8 ± 48.3 120.1 ± 48.9 40.7 ± 18.9 24.9 ± 11.1 213.7 ± 112.4 13.1 ± 3.5 0.98 ± 0.17
45 days after
Lovastatin
150.9 ± 32 83.9 ± 38.3 36.6 ± 15.6 29.0 ± 12.2 183.3 ± 78.1 3.68 ± 2.6 1.16 ± 0.29
90 day after
Lovastatin
149.3 ± 37.8 84.8 ± 43.7 30.7 ± 10.9 31.4 ± 7.7 153.4 ± 54.8 1.27 ± 1.0 1.28 ± 0.27Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/6
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patients. Recent studies have demonstrated that this lipid
peroxidation even has more important relationship with
atherosclerosis than hyperlipidemia alone [12]. The effect
may be reversible after adding of Lovastatin on the culture
medium of endothelial cells. Oxidized LDL results to
aggravate of atherosclerotic process by accumulation of
intracellular Ca++, recruitment of macrophages, to induce
cytokines and proliferation of endothelial cells. On the
other hand superoxide desmotase (SOD), catalaze and
glutathione peroxidase (GSHPX) are among the main
defensive antioxidant agents, which scavenge oxygen free
radicals in HD [13]. So they have a protective role to
development of atherosclerosis by ROS and their prod-
ucts, i.e. oxidized lipids.
Lovastatin, as a prototype of HMG-CoA inhibitors, is used
as an anti atherosclerotic drug in clinic. Although the pro-
tective role on atherosclerosis may be partially due to its
lowering effect on lipid level by inhibition of HMG-CoA
enzyme, the full story is not complete. It inhibits expres-
sion of scavenging receptors on macrophages [14], inhib-
its super oxide anion production, preserves intracellular
SOD, prevents of ROS permeation in to the lipoproteins
[9] and eventually has a preventive role on inflammation
[15]. The above assumption of anti oxidant properties of
Lovastatin was demonstrated by our study, although it
was not observed at the short term, i.e. during 45 days of
treatment. But after 3 months of Lovastatin therapy it was
an inverse linear relationship between decrement of MDA
and increased total anti oxidant activity. Our result con-
firms the previous study, which has demonstrated that
Lovastatin causes to block LDL-C oxidation of WBC in
rabbits at concentration of 10 micro mol/l [16]. This
blockage had an inverse correlation with SOD, also. On
the other hand we showed that VLDL-C and LDL-C
lipoproteins are reduced significantly after Lovastatin
consumption. HDL-C, the protective lipoprotein against
of atherosclerosis, was increased significantly only after
longer time (3 months) of Lovastatin consumption.
Hypolipoproteinemic effect of Lovastatin in 54 diabetic
Serum lipoproteins before and after beginning of Lovastatin at the end of 1.5 and 3 months Figure 1
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hamsters has been shown by Swefy etal study, also. They
found that Lovastatin and vitamin E have anti oxidant
property and decrease lipoprotein concentration after
12.5 weeks of therapy [17].
In summary we showed that dyslipoproteinemia, as a
main risk factor of atherosclerosis in ESRD, is common in
HD patients. Changes of lipoproteins in HD patients are
quantitatively (higher lipids) and qualitatively (higher
oxidized lipids) are reversible by prescription of Lovasta-
tin in these high risk patients.
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